2021
Pigmented demodicidosis ‐ an under‐recognized cause of facial hyperpigmentation
Feuerman H, Atzmony L, Glick M, Sherman S, Snast I, Hodak E, Segal R. Pigmented demodicidosis ‐ an under‐recognized cause of facial hyperpigmentation. International Journal Of Dermatology 2021, 61: 564-569. PMID: 34897670, DOI: 10.1111/ijd.15992.Peer-Reviewed Original ResearchConceptsFacial hyperpigmentationMedical files of patientsFiles of patientsOutpatient dermatology clinicBackground erythemaHistopathological featuresDermatology clinicMedical filesReticulate pigmentationDermoscopic findingsFollicular openingsFacial pigmentationHyperpigmentationHair folliclesSkin roughnessDemodicidosisPatientsDiagnostic dataErythemaFindingsCohortFolliclesClinicAffected areasInfiltration
2020
Post‐zygotic ACTB mutations underlie congenital smooth muscle hamartomas
Atzmony L, Ugwu N, Zaki TD, Antaya RJ, Choate KA. Post‐zygotic ACTB mutations underlie congenital smooth muscle hamartomas. Journal Of Cutaneous Pathology 2020, 47: 681-685. PMID: 32170967, PMCID: PMC7943230, DOI: 10.1111/cup.13683.Peer-Reviewed Original ResearchConceptsCongenital smooth muscle hamartomaSmooth muscle hamartomaBecker's nevusMuscle hamartomaBecker nevus syndromeDirect sequencingHistopathological featuresHistopathological overlapBenign lesionsMosaic disordersPhenotypic spectrumNeviUnaffected tissueAffected tissuesHamartomaPost-zygotic mutationsHemihypertrophyEnrichment assayTissueMutationsACTB gene
2009
C-reactive protein velocity following antibiotics in patients with chronic obstructive pulmonary disease exacerbation and community acquired pneumonia
Justo D, Lachmi S, Saar N, Joffe E, Atzmony L, Mashav N, Henis O, Sade B, Chundadze T, Steinvil A, Paran Y. C-reactive protein velocity following antibiotics in patients with chronic obstructive pulmonary disease exacerbation and community acquired pneumonia. European Journal Of Internal Medicine 2009, 20: 518-521. PMID: 19712857, DOI: 10.1016/j.ejim.2009.03.008.Peer-Reviewed Original ResearchConceptsCAP patientsChronic obstructive pulmonary disease exacerbationsCommunity acquired pneumoniaChronic obstructive pulmonary diseaseInitiation of antibacterial treatmentChronic obstructive pulmonary disease exacerbation patientsCRP levelsExacerbation patientsC-reactive protein velocityAntibacterial treatmentTreated with cephalosporinsChronic obstructive pulmonary disease patientsDays of hospitalizationChest X-rayInternal medicine departmentObstructive pulmonary diseaseProductive coughAntibiotic administrationDisease exacerbationStudy groupPulmonary diseaseCRPPatientsExacerbationMedicine department